Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:VIE

Viela Bio (VIE) Stock Price, News & Analysis

Viela Bio logo

About Viela Bio Stock (NASDAQ:VIE)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$53.01
$53.01
50-Day Range
$52.92
$53.20
52-Week Range
$25.02
$65.00
Volume
N/A
Average Volume
1.07 million shs
Market Capitalization
$2.91 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Viela Bio, Inc., a clinical-stage biotechnology company, engages in the research and development of treatments for severe inflammation and autoimmune diseases in the United States. The company's lead product candidate is inebilizumab, a humanized monoclonal antibody for neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases. It is also developing VIB4920 for kidney transplantation rejection and sjögren's syndrome; and VIB7734 for cutaneous lupus erythematosus. Viela Bio, Inc. has a strategic collaboration with Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases in Japan, Thailand, South Korea, Indonesia, Vietnam, Malaysia, the Philippines, Singapore, and Taiwan. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.

Remove Ads
Receive VIE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Viela Bio and its competitors with MarketBeat's FREE daily newsletter.

VIE Stock News Headlines

RGNX-Aktie erreicht 52-Wochen-Tief bei 9,28 US-Dollar
Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Regenxbio Names Mitchell Chan CFO
2024 Fire Awards: Meet this year's Ablaze honorees
See More Headlines

VIE Stock Analysis - Frequently Asked Questions

Viela Bio, Inc. (NASDAQ:VIE) released its earnings results on Sunday, February, 28th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.70) by $0.10. The firm earned $9.34 million during the quarter, compared to analysts' expectations of $5.10 million.

Viela Bio (VIE) raised $150 million in an initial public offering (IPO) on Thursday, October 3rd 2019. The company issued 7,500,000 shares at $19.00-$21.00 per share. Goldman Sachs, Morgan Stanley and Cowen served as the underwriters for the IPO and Guggenheim Securities was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Viela Bio investors own include Enovix (ENVX), Rambus (RMBS), COMPASS Pathways (CMPS), Toast (TOST), Ginkgo Bioworks (DNA), Globant (GLOB) and Saia (SAIA).

Company Calendar

Last Earnings
2/28/2021
Today
3/29/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:VIE
CIK
N/A
Fax
N/A
Employees
166
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-86,430,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$50 million
Price / Cash Flow
N/A
Book Value
$7.14 per share
Price / Book
7.42

Miscellaneous

Free Float
N/A
Market Cap
$2.91 billion
Optionable
Not Optionable
Beta
0.43
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (NASDAQ:VIE) was last updated on 3/30/2025 by MarketBeat.com Staff
From Our Partners